First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours
- 1 July 2017
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 80, 14-25
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responsesDNA Repair, 2008
- Etoposide, Topoisomerase II and CancerCurrent Medicinal Chemistry - Anti-Cancer Agents, 2005
- Etoposide: Discovery and Medicinal ChemistryCurrent Medicinal Chemistry, 2004
- Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemiaBlood, 2003
- Comprehensive Evaluation of Carboxylesterase-2 Expression in Normal Human Tissues Using Tissue Array AnalysisApplied Immunohistochemistry & Molecular Morphology, 2002
- Synthesis, Hydrolytic Activation and Cytotoxicity of Etoposide ProdrugsBioorganic & Medicinal Chemistry Letters, 2001
- Discovery of podophyllotoxinsBiochimie, 1998
- Pharmacodynamics and long-term toxicity of etoposideCancer Chemotherapy and Pharmacology, 1994
- A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposideBritish Journal of Cancer, 1992
- Low-dose oral etoposide: a new role for an old drug?Journal of Clinical Oncology, 1990